Clinical Trials Using Anti-CD38-targeted IgG4-attenuated IFNa TAK-573
Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD38-targeted IgG4-attenuated IFNa TAK-573. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)
The purpose of this study is to determine the safety and tolerability of single agent TAK-573 in participants with relapsed / refractory MM in Phase 1, and to provide a preliminary evaluation of the clinical activity of TAK-573 as a single agent and in combination with dexamethasone in participants with relapsed / refractory MM in Phase 2.
Location: 7 locations